查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2022-2029 年全球多重诊断市场
市场调查报告书
商品编码
1129254

2022-2029 年全球多重诊断市场

Global Multiplexed Diagnostics Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

各种应用的多路诊断技术的进步预计将推动市场增长。

需要准确、可靠、经济和临床相关的免疫传感器来早期检测和监测进行性疾病。多路復用传感是一种有望成为下一代诊断方法的技术。该方法允许同时检测和量化大量生物标誌物，大大提高了重现性和可靠性。与对每个生物标誌物进行单独测试相比，它还需要更小的样本量和更短的平均分析时间。例如，最常讨论的多路復用技术之一是空间多路復用，因为它可以最大限度地减少检测干扰并且与大多数测量技术兼容。场效应晶体管 (FET) 经常用作电气测量的传感机制。每个晶体管都由一个由特定抗体改变的导电或半导体通道组成。在抗原结合后，调节漏源电流，从中可以计算出目标生物标誌物的浓度。由于这些原因，预计它将成为预测期内市场的驱动力。

约束

限制因素：与多重诊断检测相关的高成本、缺乏熟练的专业人员，以及在将多重诊断检测诊断测试与传统诊断测试进行比较时，私人和政府参与者的报销规定的明确性。缺乏。因此，从上述陈述来看，预计市场在预测期内将受到阻碍。

行业分析

多重诊断市场根据波特五力、供应链分析、报销方案、产品创新和定价分析等各种行业因素对市场进行深入分析。

COVID-19 影响分析

COVID-19 大流行对医疗保健系统和市场产生了适度影响。用于实际和快速检测 SARS-CoV-2 感染的快速分子测试是一项挑战，将有助于管理当前的大流行并防止进一步爆发。冻干 LAMP 试剂用于多重和比色 RT-LAMP 检测，旨在快速灵敏地检测 SARS-CoV-2。通过病毒全基因组分析发现的一系列基因靶点促使 LAMP 引物的产生。使用最佳表征的引物组产生多重 RT-LAMP 测定。作为分析验证的一部分，还评估了检测限 (LoD)、测定内和测定间精度以及与其他呼吸道病原体的交叉反应性。因此，对多重诊断测定的需求不断增加。

另一方面，大流行会破坏供应炼和流程。许多公司将转移到其他地区以确保产品可用性并保护其供应链。因此，从上述描述来看，市场受到了影响，但随着经济活动的恢復，预计将迅速获得牵引力。

本报告提供超过 45 个市场数据表、超过 40 个图表和 180 页信息。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 各种应用的多路诊断技术的进步预计将推动市场增长。
    • 限制因素
      • 与多项目诊断相关的高成本阻碍了市场增长。
    • 机会
    • 影响分析

第五章行业分析

  • 供应链分析
  • 定价分析
  • 未满足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按产品类型

  • 试剂和耗材
  • 仪器
  • 其他

第 8 章技术

  • 低密度多重检测
  • 中浓度多重检测
  • 高密度多重检测
  • 超高密度多重检测
  • 二代测序检测
  • 其他

第 9 章。按应用程序

  • 疾病诊断
  • 分子生物学诊断
  • 药物开发
  • 其他

第 10 章，最终用户

  • 医院
  • 实验室
  • 学术和研究机构
  • 诊断中心
  • 其他

第 11 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 12 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准
  • 值得关注的重点公司列表

第 13 章公司简介

  • Luminex Corporation
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories, Inc.
  • Qiagen N.V.
  • Siemens Healthineers
  • Agilent technologies
  • BioMerieux SA
  • F.Hoffmann-La Roche Ltd
  • Hologic, Inc.
  • Illumina, Inc.

第 14 章全球多重诊断市场 - DataM

简介目录
Product Code: DMCD5801

Market Overview

The Multiplexed Diagnostics Market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Biological samples are analyzed using multiplexed diagnostics, which can finish a screening procedure in a single pass. Multiplexed diagnostic assays identify and classify various illnesses and infections, including cancer, autoimmune disorders, allergies, and cardiovascular diseases. Early detection can reduce the risk factors linked to chronic illnesses or infections and aid in effective treatment administration. Multiplexed diagnostic assays have benefits like time efficiency, high accuracy, and precision, which can detect flaws and mutations in any functioning biomolecules like DNA, RNA, and protein.

Market Dynamics

Advancement in multiplexed diagnostics for various applications is expected to drive market growth.

Clinically significant immunosensors that are accurate, dependable, and economical are required for the early detection and surveillance of progressive diseases. Multiplexed sensing is a potential approach for the coming generation of diagnostics. With this method, numerous biomarkers can be simultaneously detected and quantified with much-improved reproducibility and reliability while needing less sample material and a shorter average analysis time for each biomarker than separate tests. For instance, one of the most frequently discussed multiplexing techniques is spatial multiplexing since it minimizes detection interferences and is compatible with most measurement techniques. Field-effect transistors are frequently used as the sensing mechanism for electrical measurements (FETs). A conductive or semiconductive channel makes up each transistor, and a particular antibody has altered this channel. The drain-source current is adjusted upon the binding of the relevant antigen to the sensing channel, and from this, the concentration of the target biomarker can be calculated. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

High costs associated with multiplexed diagnostics assay, lack of availability of skilled professionals, and Comparing multiplexed assay diagnostic tests to conventional diagnostic tests, there is a lack of clarity regarding reimbursement regulations among private and governmental players. Thus, from the above statements, the market is expected to get hampered in the forecast period.

Industry Analysis

The multiplexed diagnostics market provides in-depth analysis of the market based on various industry factors such as porter's five forces, supply chain analysis, reimbursement scenario, product innovation, pricing analysis, etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. Rapid molecular testing for practical and prompt detection of SARS-CoV-2 infections is a challenge that could aid in managing the current pandemic and preventing further outbreaks. Lyophilized LAMP reagents are used in a multiplex and colorimetric RT-LAMP assay designed for the quick and sensitive detection of SARS-CoV-2. A set of gene targets found through genome-wide analysis of viruses inspired the creation of LAMP primers. A multiplex RT-LAMP assay was created using primer sets demonstrating the best features. As part of the analytical validation process, the limit of detection (LoD), intra- and inter-assay precision, and cross-reactivity with other respiratory pathogens were also evaluated. Therefore, it has increased the demand for multiplexed diagnostics assays.

In contrast, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of economic activities.

Segment Analysis

Next-Generation Sequencing Assays segment is expected to hold the largest market share in multiplexed diagnostics market

The next-generation sequencing assays segment is expected to dominate in 2021. The segment is beneficial because it has improved low-frequency variant detection sensitivity, quick turnaround times for large sample quantities, extensive genome coverage, increased sample multiplexing capability, and simultaneous sequencing of hundreds to thousands of genes or gene regions. For instance, Illumina, Inc. is an American company that develops, manufactures, and markets integrated systems to analyze genetic variation and biological function. Moreover, large numbers of libraries are pooled and sequenced concurrently using Illumina multiplex sequencing during a single run. The traditional Sanger chain-termination technique differs significantly from Illumina NGS technology's operation. It uses massively parallel sequencing by synthesis (SBS) technology, which monitors the addition of tagged nucleotides as the DNA chain is duplicated. The amount of DNA sequencing data produced by next-generation sequencing is enormous, yet it is also less expensive and time-consuming than conventional Sanger sequencing. Depending on the instrument type and setup, Illumina sequencing systems can produce data output ranging from 300 kilobases to several terabases in a single run. Therefore, it has increased the demand for next-generation sequencing technology. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global multiplexed diagnostics market

In 2021, North America accounted for the highest revenue share. The increasing prevalence of cancer, rising consumer awareness, technological advancements, quick adoption of cutting-edge diagnostic techniques, a well-defined regulatory environment, sophisticated healthcare infrastructure and product launches and acquisitions by the key market players are some factors the market is expected to boost in the forecast period. For instance, In the United States, 1,752,735 new cancer cases were reported in 2019, while 599,589 people died from the disease. Four hundred thirty-nine new cases of cancer and 146 cancer-related deaths were reported for every 100,000 persons. In contrast, in the US, 1,806,590 new cancer cases and 606,520 cancer-related deaths are anticipated in 2020, or 4,950 new cases and more than 1,600 fatalities daily.

Moreover, A US-based firm called Chembio Diagnostic Systems Inc. is creating many multiplex diagnostic technologies for managing fevers. The tests are built on the business's Dual Path Platform (DPP), a patented technology that offers superior performance to conventional lateral flow technology and simultaneous antigen and antibody detection capabilities in a disposable, quick test package. Therefore, it has increased the adoption of multiplexed diagnostics assays. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the multiplexed diagnostics market are Luminex Corporation, Thermo Fisher Scientific, Bio-Rad Laboratories, Inc., Qiagen N.V., Siemens Healthineers, Agilent technologies, BioMerieux SA, F.Hoffmann-La Roche Ltd, Hologic, Inc., Illumina, Inc.

F. Hoffmann-La Roche Ltd:

Overview:

Hoffmann-La Roche Ltd is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. It is one of the largest biotech companies, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology, and neuroscience. It is a global leader in in-vitro and tissue-based cancer diagnostics and a frontrunner in diabetes management. Its personalized healthcare strategy aims to provide medicines and diagnostics that enable tangible improvements in patients' health, quality of life and survival. Moreover, Roche Molecular, one of four customer-focused areas of Roche Diagnostics Solutions, develops, manufactures and supplies a wide array of innovative molecular diagnostic products, tests, platforms and technologies used to identify and quantify DNA and RNA from different organisms.

Product Portfolio:

eSensor Technology: The eSensor Technology is based on competitive DNA hybridization and electrochemical detection principles. eSensor Technology is highly specific for the target biomarker and is not based on fluorescent or optical detection. As a result, diagnostic tests are less prone to sample contamination risk and do not require time-consuming washing and preparation steps.

The global multiplexed diagnostics market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Advancement in multiplexed diagnostics for various applications is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. High costs associated with multiplexed diagnostics assay is expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type Segment
  • 7.2. Reagents & Consumables*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Instruments
  • 7.4. Others

8. By Technology

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 8.1.2. Market Attractiveness Index, By Technology Segment
  • 8.2. Low Density Multiplexed Assays*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Medium Density Multiplexed Assays
  • 8.4. High Density Multiplexed Assays
  • 8.5. Very High Density Multiplexed Assays
  • 8.6. Next-Generation Sequencing Assays
  • 8.7. Others

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application Segment
  • 9.2. Disease Diagnostics*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Molecular Diagnostics
  • 9.4. Drug Development
  • 9.5. Others

10. By End user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Clinical Laboratories
  • 10.4. Academic & Research Institutes
  • 10.5. Diagnostic Centers
  • 10.6. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Luminex Corporation*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Thermo Fisher Scientific
  • 13.3. Bio-Rad Laboratories, Inc.
  • 13.4. Qiagen N.V.
  • 13.5. Siemens Healthineers
  • 13.6. Agilent technologies
  • 13.7. BioMerieux SA
  • 13.8. F.Hoffmann-La Roche Ltd
  • 13.9. Hologic, Inc.
  • 13.10. Illumina, Inc.

LIST NOT EXHAUSTIVE

14. Global Multiplexed Diagnostics Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Applications
  • 14.3. Contact Us